title: Therapeutic challenges of pancreatic ascites and the role of endoscopic pancreatic stenting.
abstract: Management of pancreatic ascites poses significant therapeutic challenges. Treatment usually consists of either conservative management or interventional therapy with little consensus between the two options. Conservative therapy is the most common initial treatment option but has high failure rates hence arguing for interventional therapy as a preferred primary treatment option. Endoscopic treatment is particularly appealing due to lower failure rates and mortality than conservative therapy or surgery. We describe a patient with recurrent pancreatic ascites who was successfully managed with endoscopic transpapillary stenting. This report contributes to the limited but growing literature on the management of pancreatic ascites.
authors.affiliation: Department of Hospital Medicine, Oregon Health and Science University, Portland, Oregon, USA.
authors.forename: Sudhakar
authors.initials: S
authors.lastname: Karlapudi
authors.affiliation: School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
authors.forename: Tomoya
authors.initials: T
authors.lastname: Hinohara
authors.affiliation: Department of Hospital Medicine, Oregon Health and Science University, Portland, Oregon, USA.
authors.forename: James
authors.initials: J
authors.lastname: Clements
authors.affiliation: Department of Gastroenterology, Oregon Health & Science University, Portland, Oregon, USA.
authors.forename: Gene
authors.initials: G
authors.lastname: Bakis
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001201:Ascites / Q000601:surgery*; D001424:Bacterial Infections / Q000188:drug therapy; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects; D006801:Humans; D008297:Male; D000077731:Meropenem; D010182:Pancreatic Diseases / Q000601:surgery*; D012008:Recurrence; D015607:Stents; D013845:Thienamycins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000077731:Meropenem